PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP® biotherapy at the “Electrochemotherapy 1st International Users’ Meeting”(Bologna, Italy, November 19-20, 2010).
